NJEDA – NJ Manufacturing Award Will Support Amneal Pharmaceuticals’ Expansion
Amneal Pharmaceuticals plans to invest more than $240 million and create 330+ new full-time jobs in Piscataway.
The New Jersey Economic Development Authority (NJEDA) Board recently approved approximately $60 million in tax credits under the Next New Jersey Manufacturing Program to support a planned manufacturing expansion by Amneal Pharmaceuticals, a global biopharmaceutical company focused on developing, manufacturing, commercializing, and distributing affordable and innovative medicines. Headquartered in Bridgewater, Amneal plans to expand its manufacturing operations in Piscataway. The project represents more than $240 million in eligible capital investment over three years and is expected to create more than 330 new full-time jobs in New Jersey, further strengthening the state’s position as a national leader in pharmaceutical manufacturing and innovation.
Amneal has a portfolio of more than 300 generic, specialty, and biosimilar medicines and delivers more than 160 million prescriptions annually. The expansion is designed to support continued growth in Amneal’s Affordable Medicines business, including complex generics, women’s health, and new product launches, as well as the continued advancement of its biosimilars portfolio. The project includes significant investments to expand manufacturing capabilities for transdermal patches, biosimilars, and pharmaceutical injectables.